MENU
+Compare
RGNX
Stock ticker: NASDAQ
AS OF
Nov 20, 04:59 PM (EDT)
Price
$10.87
Change
-$0.06 (-0.55%)
Capitalization
550.02M

RGNX REGENXBIO Forecast, Technical & Fundamental Analysis

Regenxbio Inc is a biotechnology company... Show more

Industry: #Biotechnology
RGNX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for RGNX with price predictions
Nov 19, 2025

RGNX sees MACD Histogram crosses below signal line

RGNX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 31, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 52 instances where the indicator turned negative. In of the 52 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 03, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RGNX as a result. In of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

RGNX moved below its 50-day moving average on November 19, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RGNX advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 138 cases where RGNX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.407) is normal, around the industry mean (27.606). P/E Ratio (0.000) is within average values for comparable stocks, (52.154). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.053). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (3.459) is also within normal values, averaging (329.190).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
RGNX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

RGNX is expected to report earnings to fall 38.52% to -73 cents per share on March 03

REGENXBIO RGNX Stock Earnings Reports
Q4'25
Est.
$-0.74
Q3'25
Beat
by $0.10
Q2'25
Missed
by $0.44
Q1'25
Missed
by $0.36
Q4'24
Beat
by $0.12
The last earnings report on November 06 showed earnings per share of -120 cents, beating the estimate of -129 cents. With 443.81K shares outstanding, the current market capitalization sits at 550.02M.
A.I. Advisor
published General Information

General Information

a developer of gene therapy treatments

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
9804 Medical Center Drive
Phone
+1 240 552-8181
Employees
344
Web
https://www.regenxbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CPCCX4.11N/A
N/A
Comstock Capital Value C
SVSPX289.87N/A
N/A
State Street S&P 500 Index N
CSXCX51.36N/A
N/A
Calvert US Large Cap Core Rspnb Idx C
WPGSX11.21N/A
N/A
WPG Partners Select Small Cap Value Ins
MMNJX16.42N/A
N/A
MassMutual Small Cap Gr Eq Y

RGNX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-2.84%
SYRE - RGNX
56%
Loosely correlated
+0.83%
DNLI - RGNX
56%
Loosely correlated
-3.20%
RXRX - RGNX
54%
Loosely correlated
-3.12%
ARWR - RGNX
54%
Loosely correlated
-3.71%
BEAM - RGNX
54%
Loosely correlated
-4.24%
More